文献速递神经肿瘤

面神经保留策略治疗小脑脑桥角脑膜瘤的疗效与结局

Efficacy and outcomes of facial nerve-sparing treatment approach to cerebellopontine angle meningiomas.
PubMed 文献 · J Neurosurg · 2017-02-10

该研究回顾性分析1992至2016年单术者治疗的76例小脑脑桥角脑膜瘤患者,按肿瘤大小选择伽玛刀放射外科(GKRS,<2.5 cm)或面神经保留显微手术(≥2.5 cm)。51例(67.1%)手术,25例(32.9%)GKRS;68例(89.5%)面神经功能不变或改善,8例(10.5%)恶化且均发生于手术组。GKRS治疗<2.5 cm肿瘤在46个月中位随访中全部保留面神经功能。

要点

  • 肿瘤<2.5 cm者首选GKRS,≥2.5 cm者行面神经保留显微手术。
  • 手术治疗51例中,全切除34例(66.7%),次全切除17例(33.3%)。
  • 术后12例(23.5%)复发,需再次手术和/或GKRS。

核心结论

  • GKRS是治疗<2.5 cm且无占位效应或急性神经症状的小脑脑桥角脑膜瘤的安全有效选择。
  • ≥2.5 cm肿瘤可行最大安全切除并保留神经功能,无显著面神经功能障碍风险,联合GKRS可提供良好疾病控制。
  • 肿瘤起源的解剖特征为优化面神经保留提供关键信息。

研究设计与样本

  • 回顾性研究,纳入1992至2016年单术者治疗的76例影像学或术后诊断的小脑脑桥角脑膜瘤患者。
  • 肿瘤最大径<2.5 cm者行GKRS,≥2.5 cm者酌情行面神经保留显微手术。

主要发现

  • 51例(67.1%)行显微手术,25例(32.9%)行GKRS。
  • 手术组中全切除34例(66.7%),次全切除17例(33.3%)。
  • 术后12例(23.5%)复发,需再次手术和/或GKRS。
  • 面神经功能不变或改善68例(89.5%),恶化8例(10.5%),恶化者均来自手术组。
  • GKRS治疗<2.5 cm肿瘤在46个月中位随访中全部保留面神经功能,与内听道侵犯和肿瘤起源无关。

关键数值与推荐

  • 肿瘤大小、切除程度及肿瘤与内听道内容物之间的蛛网膜平面与术后面神经结局相关。
  • 肿瘤解剖起源与切除程度相关,但与术后面神经功能无关。

临床怎么用

  • 对于<2.5 cm且无占位效应或急性神经症状的小脑脑桥角脑膜瘤,GKRS是安全有效的选择。
  • 对于≥2.5 cm肿瘤,可行最大安全切除以保留神经功能,联合GKRS处理复发和/或进展可提供良好疾病控制。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Advanced microsurgical techniques contribute to reduced morbidity and improved surgical management of meningiomas arising within the cerebellopontine angle (CPA). However, the goal of surgery has evolved to preserve the quality of the patient's life, even if it means leaving residual tumor. Concurrently, Gamma Knife radiosurgery (GKRS) has become an acceptable and effective treatment modality for newly diagnosed, recurrent, or progressive meningiomas of the CPA. The authors review their institutional experience with CPA meningiomas treated with GKRS, surgery, or a combination of surgery and GKRS. They specifically focus on rates of facial nerve preservation and characterize specific anatomical features of tumor location with respect to the internal auditory canal (IAC). METHODS Medical records of 76 patients with radiographic evidence or a postoperative diagnosis of CPA meningioma, treated by a single surgeon between 1992 and 2016, were retrospectively reviewed. Patients with CPA meningiomas smaller than 2.5 cm in greatest dimension were treated with GKRS, while patients with tumors 2.5 cm or larger underwent facial nerve-sparing microsurgical resection where appropriate. Various patient, clinical, and tumor data were gathered. Anatomical features of the tumor origin as seen on preoperative imaging confirmed by intraoperative investigation were evaluated for prognostic significance. Facial nerve preservation rates were evaluated. RESULTS According to our treatment paradigm, 51 (67.1%) patients underwent microsurgical resection and 25 (32.9%) patients underwent GKRS. Gross-total resection (GTR) was achieved in 34 (66.7%) patients, and subtotal resection (STR) in 17 (33.3%) patients. Tumors recurred in 12 (23.5%) patients initially treated surgically, requiring additional surgery and/or GKRS. Facial nerve function was unchanged or improved in 68 (89.5%) patients. Worsening facial nerve function occurred in 8 (10.5%) patients, all of whom had undergone microsurgical resection. Upfront treatment with GKRS for CPA meningiomas smaller than 2.5 cm was associated with preservation of facial nerve function in all patients over a median follow-up of 46 months, regardless of IAC invasion and tumor origin. Anatomical origin was associated with extent of resection but did not correlate with postoperative facial nerve function. Tumor size, extent of resection, and the presence of an arachnoid plane separating the tumor and the contents of the IAC were associated with postoperative facial nerve outcomes. CONCLUSIONS CPA meningiomas remain challenging lesions to treat, given their proximity to critical neurovascular structures. GKRS is a safe and effective option for managing CPA meningiomas smaller than 2.5 cm without associated mass effect or acute neurological symptoms. Maximal safe resection with preservation of neurological function can be performed for tumors 2.5 cm or larger without significant risk of facial nerve dysfunction, and, when combined with GKRS for recurrence and/or progression, provides excellent disease control. Anatomical features of the tumor origin offer critical insights for optimizing facial nerve preservation in this cohort.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. D'Amico RS, Banu MA, Petridis P, et al. Efficacy and outcomes of facial nerve-sparing treatment approach to cerebellopontine angle meningiomas. J Neurosurg. 2017. PMID: 28186449. doi:10.3171/2016.10.JNS161982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。